• Consensus Rating: Buy
  • Consensus Price Target: $183.80
  • Forecasted Upside: 14.93 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$159.93
▼ -5.61 (-3.39%)

This chart shows the closing price for MASI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Masimo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MASI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MASI

Analyst Price Target is $183.80
▲ +14.93% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Masimo in the last 3 months. The average price target is $183.80, with a high forecast of $295.00 and a low forecast of $135.00. The average price target represents a 14.93% upside from the last price of $159.93.

This chart shows the closing price for MASI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Masimo. This rating has held steady since January 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2022Needham & Company LLCBoost TargetBuy$163.00 ➝ $179.00Low
8/10/2022Piper SandlerBoost TargetNeutral$130.00 ➝ $135.00Low
5/4/2022Stifel NicolausLower Target$175.00 ➝ $150.00Medium
5/4/2022Needham & Company LLCLower Target$205.00 ➝ $163.00High
5/4/2022Piper SandlerLower Target$160.00 ➝ $130.00High
4/5/2022Wolfe ResearchInitiated CoverageMarket Perform$160.00Low
3/31/2022Stifel NicolausLower TargetBuy$250.00 ➝ $175.00High
3/17/2022Piper SandlerLower TargetNeutral$200.00 ➝ $160.00High
2/18/2022Needham & Company LLCUpgradeHold ➝ Buy$205.00High
2/16/2022UBS GroupLower TargetBuy$325.00 ➝ $295.00High
2/16/2022Piper SandlerDowngradeOverweight ➝ Neutral$330.00 ➝ $200.00High
11/15/2021Piper SandlerBoost TargetOverweight$320.00 ➝ $330.00Low
10/27/2021Piper SandlerBoost TargetPositive ➝ Overweight$300.00 ➝ $320.00Low
10/12/2021Raymond JamesInitiated CoverageMarket PerformHigh
7/28/2021Piper SandlerBoost TargetOverweight$295.00 ➝ $300.00Low
4/29/2021Robert W. BairdReiterated RatingBuy$310.00Low
3/24/2021Piper SandlerLower TargetOverweight$310.00 ➝ $295.00Low
1/29/2021Raymond JamesBoost TargetOutperform$275.00 ➝ $285.00Low
1/14/2021Piper SandlerBoost TargetOverweight$280.00 ➝ $310.00High
10/28/2020Stifel NicolausBoost TargetBuy$255.00 ➝ $276.00High
10/28/2020Raymond JamesBoost TargetOutperform$250.00 ➝ $275.00High
10/28/2020Piper SandlerBoost TargetOverweight$250.00 ➝ $280.00High
10/6/2020Needham & Company LLCReiterated RatingHoldHigh
9/16/2020Raymond JamesReiterated RatingBuyLow
9/1/2020Robert W. BairdInitiated CoverageOutperform$260.00High
7/29/2020Stifel NicolausBoost TargetBuy$245.00 ➝ $255.00High
7/29/2020Raymond JamesBoost TargetOutperform$235.00 ➝ $250.00High
7/9/2020BTIG ResearchReiterated RatingHoldLow
6/26/2020Raymond JamesReiterated RatingBuyMedium
4/30/2020UBS GroupBoost TargetBuy$207.00 ➝ $245.00Medium
4/29/2020Stifel NicolausBoost TargetBuy$200.00 ➝ $245.00High
4/20/2020Needham & Company LLCDowngradeBuy ➝ HoldMedium
4/1/2020Needham & Company LLCReiterated RatingBuy$201.00Low
3/24/2020Needham & Company LLCReiterated RatingBuy$201.00Low
3/2/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$183.00High
2/20/2020Piper SandlerBoost Target$175.00 ➝ $201.00Low
2/20/2020Needham & Company LLCBoost TargetBuy$182.00 ➝ $201.00Medium
2/20/2020UBS GroupBoost TargetBuy$190.00 ➝ $207.00Medium
1/15/2020Piper SandlerReiterated RatingBuy$175.00Low
1/15/2020UBS GroupBoost TargetBuy$180.00 ➝ $190.00High
12/17/2019Piper Jaffray CompaniesReiterated RatingOverweight$161.00 ➝ $175.00Low
8/1/2019Stifel NicolausBoost TargetBuy$165.00 ➝ $170.00Medium
8/1/2019UBS GroupBoost TargetBuy$172.00 ➝ $180.00Medium
8/1/2019BTIG ResearchReiterated RatingHoldHigh
5/17/2019Stifel NicolausBoost TargetBuy$150.00 ➝ $160.00Low
5/17/2019Piper Jaffray CompaniesBoost Target$148.00 ➝ $160.00Low
5/7/2019UBS GroupBoost TargetBuy ➝ Buy$147.00 ➝ $160.00High
5/7/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$155.00 ➝ $158.00High
5/7/2019Piper Jaffray CompaniesBoost TargetOverweight$140.00 ➝ $148.00High
4/16/2019BTIG ResearchDowngradeBuy ➝ Neutral$134.50High
4/9/2019Needham & Company LLCReiterated RatingBuyLow
3/13/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$148.00 ➝ $155.00Medium
2/27/2019Piper Jaffray CompaniesReiterated RatingOverweight$140.00High
2/1/2019Needham & Company LLCReiterated RatingBuy$139.00Low
12/19/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$120.00Medium
11/27/2018UBS GroupInitiated CoverageBuy$137.00High
11/1/2018Piper Jaffray CompaniesBoost TargetNeutral$120.00High
10/2/2018Stifel NicolausBoost TargetBuy ➝ Buy$112.00 ➝ $145.00Low
9/14/2018Needham & Company LLCInitiated CoverageBuy ➝ BuyHigh
8/2/2018Stifel NicolausBoost TargetBuy ➝ Buy$108.00 ➝ $112.00High
5/3/2018BTIG ResearchReiterated RatingBuy$100.00High
5/2/2018Piper Jaffray CompaniesBoost TargetNeutral$94.00High
3/9/2018BarclaysInitiated CoverageOverweight ➝ Overweight$97.00Medium
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$91.00High
11/3/2017Stifel NicolausReiterated RatingBuy$108.00N/A
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
1/21/2022
  • 12 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
2/20/2022
  • 2 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/22/2022
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/21/2022
  • 7 very positive mentions
  • 28 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
5/21/2022
  • 6 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2022
  • 6 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/20/2022
  • 5 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/19/2022

Current Sentiment

  • 5 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Masimo logo
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $159.93
Low: $159.52
High: $165.98

50 Day Range

MA: $139.65
Low: $122.02
High: $169.38

52 Week Range

Now: $159.93
Low: $112.07
High: $305.21

Volume

1,083,935 shs

Average Volume

1,221,637 shs

Market Capitalization

$8.40 billion

P/E Ratio

48.17

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Masimo?

The following sell-side analysts have issued reports on Masimo in the last twelve months: Needham & Company LLC, Piper Sandler, Raymond James, Stifel Nicolaus, StockNews.com, TheStreet, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for MASI.

What is the current price target for Masimo?

5 Wall Street analysts have set twelve-month price targets for Masimo in the last year. Their average twelve-month price target is $183.80, suggesting a possible upside of 14.9%. UBS Group AG has the highest price target set, predicting MASI will reach $295.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $135.00 for Masimo in the next year.
View the latest price targets for MASI.

What is the current consensus analyst rating for Masimo?

Masimo currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MASI will outperform the market and that investors should add to their positions of Masimo.
View the latest ratings for MASI.

What other companies compete with Masimo?

Other companies that are similar to Masimo include LivaNova, CONMED, InMode, Dr. Reddy's Laboratories and NovoCure. Learn More about companies similar to Masimo.

How do I contact Masimo's investor relations team?

Masimo's physical mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider's listed phone number is (949) 297-7000 and its investor relations email address is [email protected] The official website for Masimo is www.masimo.com. Learn More about contacing Masimo investor relations.